RELAPSING REMITTING MULTIPLE SCLEROSIS
Clinical trials for RELAPSING REMITTING MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new RELAPSING REMITTING MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with MS: drug trial targets relapses
Disease control Not yet recruitingThis study tests a drug called ocrelizumab in children and teens aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see how the drug works in the body, if it is safe, and how well it controls MS attacks. Participants will receive injections over 48 wee…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 04:05 UTC
-
Double-Drug strike aims to halt MS early
Disease control Not yet recruitingThis study tests whether giving two strong medications one after the other can safely control relapsing-remitting multiple sclerosis (MS) in its early stages. Sixty adults aged 18-50 with active MS will receive rituximab infusions followed by cladribine tablets, then be monitored…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Uppsala University • Aim: Disease control
Last updated May 11, 2026 20:52 UTC